Results 1 to 10 of about 11,507 (165)

Role of Bruton’s tyrosine kinase in B cells and malignancies [PDF]

Molecular Cancer, 2018
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Simar Pal Singh, Floris Dammeijer, Rudi W. Hendriks   +2 more
doaj   +15 more sources

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. [PDF]

PLoS ONE, 2017
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic protein tyrosine kinase with a fundamental role in B-lymphocyte development and activation. The nucleocytoplasmic shuttling of BTK is specifically modulated by the Ankyrin Repeat Domain 54 (ANKRD54) protein
Manuela O Gustafsson, Dara K Mohammad, Erkko Ylösmäki, Hyunseok Choi, Subhash Shrestha, Qing Wang, Beston F Nore, Kalle Saksela, C I Edvard Smith   +8 more
doaj   +4 more sources

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis [PDF]

Therapeutic Advances in Neurological Disorders
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl   +8 more
doaj   +2 more sources

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis [PDF]

Arthritis Research & Therapy, 2023
Background Bruton’s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fcγ receptor (FcγR)-mediated signal transduction.
Issei Nakade, Yuto Tamura, Fuyu Hashimoto, Yuko Ariza, Shingo Hotta, Hirofumi Fujigaya, Suishin Arai, Mai Taniguchi, Hodaka Ogawa, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Akihiro Ishizu   +13 more
doaj   +2 more sources

Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia [PDF]

Journal of Neuroinflammation
Chronic cerebral hypoperfusion (CCH), a disease afflicting numerous individuals worldwide, is a primary cause of cognitive deficits, the pathogenesis of which remains poorly understood. Bruton’s tyrosine kinase inhibition (BTKi) is considered a promising
Lu-Lu Xu, Sheng Yang, Luo-Qi Zhou, Yun-Hui Chu, Xiao-Wei Pang, Yun-Fan You, Hang Zhang, Lu-Yang Zhang, Li-Fang Zhu, Lian Chen, Ke Shang, Jun Xiao, Wei Wang, Dai-Shi Tian, Chuan Qin   +14 more
doaj   +2 more sources

Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, Fumihito Hosoi   +9 more
doaj   +2 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and ...
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, Dariusz Pawlak   +4 more
doaj   +1 more source